Cellectis (CLLS) Prices 8.8M ADS Offering at $2.50/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Cellectis Announces Pricing of Follow-On Offering
February 3, 2023 12:48 AM ESTNEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Cellectis or the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (ADS), each representing the right to receive one ordinary share of Cellectis, nominal value 0.05 per share (the Global Offering), comprised of a public offering of ADS in the United States of America only and a private placement in other countries... More
